Related Experiment Videos
The use of methotrexate in polymyalgia rheumatica
H L Feinberg1, J D Sherman, C G Schrepferman
1Ashland Arthritis Center, Kentucky, USA.
The Journal of Rheumatology
|September 1, 1996
Abstract
Objective:
To examine the efficacy and steroid sparing potential of methotrexate (MTX) in the treatment of polymyalgia rheumatica (PMR) without giant cell arteritis.
Methods:
43 patients with PMR were treated with MTX 7.5 mg/wk for 3 months. This dose was raised to 10 and finally 12.5 mg/wk MTX if the desired response was not obtained.
Results:
No patient benefitted clinically or statistically from treatment with MTX.
Conclusion:
MTX is of no benefit in the treatment of PMR.